Safety and tolerability of bosentan in adults with Eisenmenger physiology

被引:72
作者
Gatzoulis, MA
Rogers, P
Li, W
Harries, C
Cramer, D
Ward, S
Mikhail, GW
Simon, J
Gibbs, R
机构
[1] Royal Brompton & Natl Heart Hosp, Adult Congenital Heart Program, London SW3 6NP, England
[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England
[3] Royal Brompton Hosp, Dept Resp Physiol, London SW3 6LY, England
关键词
Eisenmenger; pulmonary hypertension; bosentan; endothelin antagonists;
D O I
10.1016/j.ijcard.2004.08.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bosentan, a dual-endothelin receptor antagonist, is an established treatment for pulmonary arterial hypertension. We hypothesized that bosentan is safe and well tolerated in patients with Eisenmenger physiology. Methods: In this pilot open-label study, we primarily examined safety and tolerability of oral bosentan. Patients were recruited from our adult congenital heart clinic following informed consent. Baseline and 3-month assessment included WHO functional class, resting oxygen saturations, 6-min walk test, transthoracic echocardiography and respiratory mass spectrometry. Patient clinical status and liver enzymes were closely monitored throughout. Results: All 10 study patients (42 +/- 4 years; eight female) tolerated bosentan well. No major adverse events or significant liver enzyme elevations were observed. All but one patient felt better; none felt worse. Four patients experienced transient leg oedema. Resting oxygen saturations (83 +/- 5 versus 80 +/- 5%; P=0.011) and the distance travelled in the 6-min walk test (348 +/- 112 versus 249 +/- 117 m; P=0.004) increased relative to baseline. Changes in echocardiographic parameters (maximum aortic forward flow velocity 1.3 +/- 0.1 versus 1.1 +/- 0.2 ms, P=0.013; pulmonary arterial acceleration time 66 +/- 10 versus 58 +/- 12 m/s, P=0.02) and pulmonary blood flow (3.45 +/- 1.2 versus 2.58 +/- 1.0 L/min, P=0.008) suggested improved pulmonary haemodynamics by study end. Other echocardiographic changes suggested improved right ventricular systolic function (septal amplitude 1.0 versus 1.1 cm, P=0.048; systolic tissue Doppler velocity 4.8 versus 2.3 cm s(-1), P=0.002) by study end. Conclusions: Bosentan was safe and well tolerated in adults with Eisenmenger physiology both at initiation and after 3 months of oral therapy. Clinical status of patients and pulmonary haemodynamics appeared to improve, and this warrants further investigation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:147 / 151
页数:5
相关论文
共 25 条
[1]  
ADATIA I, 1993, BRIT HEART J, V69, P233
[2]  
Bando K, 1997, CIRCULATION, V96, P346
[3]   Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease [J].
Bolger, AP ;
Sharma, R ;
Li, W ;
Leenarts, M ;
Kalra, PR ;
Kemp, M ;
Coats, AJS ;
Anker, SD ;
Gatzoulis, MA .
CIRCULATION, 2002, 106 (01) :92-99
[4]   Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].
Channick, RN ;
Simonneau, G ;
Sitbon, O ;
Robbins, IM ;
Frost, A ;
Tapson, VF ;
Badesch, DB ;
Roux, S ;
Rainisio, M ;
Bodin, F ;
Rubin, LJ .
LANCET, 2001, 358 (9288) :1119-1123
[5]   Eisenmenger syndrome - Factors relating to deterioration and death [J].
Daliento, L ;
Somerville, J ;
Presbitero, P ;
Menti, L ;
Brach-Prevert, S ;
Rizzoli, G ;
Stone, S .
EUROPEAN HEART JOURNAL, 1998, 19 (12) :1845-1855
[6]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[7]   Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology [J].
Fernandes, SM ;
Newburger, JW ;
Lang, P ;
Pearson, DD ;
Feinstein, JA ;
Gauvreau, K ;
Landzberg, MJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (05) :632-635
[8]  
Gibbs JSR, 2001, HEART, V86, pI1
[9]  
GUYATT GH, 1985, CAN MED ASSOC J, V132, P919
[10]   Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension [J].
Hoeper, MM ;
Maier, R ;
Tongers, J ;
Niedermeyer, J ;
Hohlfeld, JM ;
Hamm, M ;
Fabel, H .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (02) :535-541